CryoCell International (CCEL)
(Delayed Data from AMEX)
$6.20 USD
-0.29 (-4.47%)
Updated Aug 30, 2024 11:35 AM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for CryoCell International Inc falls in the month of November.
All items in Millions except Per Share data.
11/30/2023 | 11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1 | 2 | 8 | 10 | 7 |
Receivables | 7 | 6 | 5 | 6 | 6 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 1 | 1 | 1 | 1 |
Other Current Assets | 1 | 1 | 1 | 1 | 1 |
Total Current Assets | 9 | 10 | 16 | 19 | 15 |
Net Property & Equipment | 21 | 14 | 3 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 5 | 9 | 10 | 11 | 13 |
Deferred Charges | 20 | 14 | 12 | 10 | 9 |
Intangibles | 3 | 17 | 18 | 3 | 3 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 0 |
Total Assets | 61 | 65 | 61 | 46 | 43 |
Liabilities & Shareholders Equity | 11/30/2023 | 11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 2 | 3 | 3 |
Accounts Payable | 3 | 2 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 1 | 2 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 5 | 4 | 3 | 3 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 11 | 12 | 14 | 9 | 9 |
Total Current Liabilities | 21 | 19 | 21 | 16 | 15 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 41 | 36 | 31 | 27 | 24 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 8 | 9 | 0 | 3 | 6 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 2 | 4 | 2 | 5 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 72 | 66 | 56 | 49 | 50 |
Shareholders Equity | 11/30/2023 | 11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 43 | 43 | 42 | 37 | 36 |
Retained Earnings | -31 | -22 | -17 | -19 | -22 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 23 | 23 | 21 | 21 | 21 |
Total Shareholder's Equity | -11 | -2 | 4 | -3 | -7 |
Total Liabilities & Shareholder's Equity | 61 | 65 | 61 | 46 | 43 |
Total Common Equity | -11 | -2 | 4 | -3 | -7 |
Shares Outstanding | 8.20 | 8.50 | 8.50 | 7.50 | 7.80 |
Book Value Per Share | -1.35 | -0.18 | 0.49 | -0.36 | -0.89 |
Fiscal Year End for CryoCell International Inc falls in the month of November.
All items in Millions except Per Share data.
5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2 | 1 | 1 | 1 | 2 |
Receivables | 7 | 7 | 7 | 6 | 7 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 1 | 1 | 1 | 1 |
Other Current Assets | 1 | 1 | 1 | 1 | 1 |
Total Current Assets | 10 | 9 | 9 | 10 | 10 |
Net Property & Equipment | 22 | 22 | 21 | 19 | 17 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 5 | 5 | 5 | 9 | 9 |
Deferred Charges | 20 | 20 | 20 | 14 | 14 |
Intangibles | 3 | 3 | 3 | 16 | 17 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 63 | 62 | 61 | 70 | 69 |
Liabilities & Shareholders Equity | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 3 | 3 | 3 | 4 |
Current Portion Long-Term Debt | 4 | 2 | 1 | 3 | 2 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 4 | 5 | 2 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 10 | 10 | 11 | 11 | 11 |
Total Current Liabilities | 19 | 19 | 21 | 19 | 20 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 44 | 43 | 41 | 40 | 39 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 8 | 8 | 8 | 8 | 9 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 2 | 2 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 73 | 72 | 72 | 70 | 70 |
Shareholders Equity | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 44 | 44 | 43 | 43 | 43 |
Retained Earnings | -30 | -31 | -31 | -20 | -21 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 25 | 24 | 23 | 23 | 23 |
Total Shareholder's Equity | -11 | -10 | -11 | 0 | -1 |
Total Liabilities & Shareholder's Equity | 63 | 62 | 61 | 70 | 69 |
Total Common Equity | -11 | -10 | -11 | 0 | -1 |
Shares Outstanding | 8.10 | 8.20 | 8.20 | 8.20 | 8.30 |
Book Value Per Share | -1.33 | -1.26 | -1.35 | 0.00 | -0.10 |